Abstract:Abstract Abstract 906 Introduction: Sickle cell disease (SCD) is a devastating inherited hemolytic disorder due to a single missense mutation in the β-globin gene resulting in the production of hemoglobin S (HbS). Despite our knowledge of the molecular defect in HbS, we remain unable to control HbS polymerization and erythrocyte sickling under hypoxic conditions, which are central to the pathophysiology of the disease. Methods and Results: Here we report that adenosine, a cellular metabolite that is well known to be induced under hypoxic/ischemic conditions, is increased in the blood circulation of patients with SCD and in SCD transgenic (Tg) mice. To our surprise, we found that adenosine contributes to hypoxia-induced sickling of cultured erythrocytes from humans with SCD. Next, to evaluate the pathogenic role of increased adenosine in erythrocyte signaling in vivo, we took advantage of SCD transgenic (Tg) mice, a well accepted animal model of SCD. Intriguingly, treatment of SCD Tg mice with polyethylene glycol-modified adenosine deaminase (PEG-ADA) enzyme therapy to lower circulating adenosine levels reduced sickling and attenuated multiple tissue damage (including lung, kidney, liver and spleen) seen in SCD Tg mice. These findings revealed a previously unrecognized role for excess adenosine in sickling and the progression to multiple life-threatening complications. Next, by screening erythrocytes for small metabolites that are induced by adenosine and may contribute to sickling, we determined that 2,3-diphosphoglycerate (2,3-DPG), an erythroid specific metabolite known to promote O2 release from Hb, is elevated in erythrocytes of both SCD Tg mice and humans. Using both pharmacological and genetic approaches, we demonstrated that adenosine-mediated 2,3-DPG induction is through A2B receptor signaling and that this signaling pathway is a major contributor to hypoxia-induced erythrocyte sickling. Conclusion and Significance: Overall, we have identified for the first time that elevated adenosine induces 2,3-DPG via A2BR signaling and contributes to sickling in both human and mouse with SCD. Thus, our studies provide strong support for the new concept that adenosine-mediated 2,3-DPG induction is beneficial for normal erythrocytes by promoting O2 release from Hb to hypoxic tissues. However, for SCD patients, the beneficial effect of adenosine-mediated 2,3-DPG induction becomes detrimental by inducing erythrocyte sickling due to 2,3-DPG mediated increased O2 release and increased deoxyHbS polymerization. Our findings reveal a novel therapeutic possibility to treat and prevent sickling and progression to multiple life-threatening complications by targeting on the adenosine signaling pathway. Disclosures: No relevant conflicts of interest to declare.

Sickle Cell Hemoglobin Drugged with Cyclic Peptides is Aggregation Incompetent

Sickle Cell Hemoglobin "Drugged" with Cyclic Peptides Is Aggregation Incompetent

Cyclic Peptides as Aggregation Inhibitors for Sickle Cell Disease

Detrimental Role of Excess Adenosine-Mediated 2,3-Diphosphoglycerate Induction in Erythrocyte Sickling and Novel Mechanism-Based Therapies.

On the Binding Free Energy and Molecular Origin of Sickle Cell Hemoglobin Aggregation

Regioselective covalent modification of hemoglobin in search of antisickling agents

Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action

Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease

Science Journals — AAAS

Evaluating sheep hemoglobins with MD simulations as an animal model for sickle cell disease

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions

Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.

Simultaneous polymerization and adhesion under hypoxia in sickle cell disease.

Quantitative Model‐Based Assessment of Multiple Sickle Cell Disease Therapeutic Approaches Alone and in Combination

Methemoglobin aggregation is modulated by the anti-sickling drug voxelotor

Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease

PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease

Probing the Twisted Structure of Sickle Hemoglobin Fibers via Particle Simulations.

In-Silico structural analysis of wild-type human hemoglobin and its mutation resulting in sickle cell anemia

Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia

Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities